This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

23 Jul 2012

RegeneRx And Lee's Reach License Agreement for TB4-based Products

RegeneRx and Lee's Pharmaceuticals have announced a licensing agreement for RegeneRx's TB4-based products in China (including Hong Kong and Macau) and Taiwan.

RegeneRx Biopharmaceuticals has entered into a licensing agreement with Lee's Pharmaceutical (HK) Ltd for the former's Thymosin Beta 4-based products.


Under the terms of the deal, Lee's will pay for all development costs associated with each product candidate, including RGN-259, RGN-352 and RGN-137, in China, Hong Kong, Macau and Taiwan.


Lee's has already paid $200,000 to RegeneRx and will pay a further $200,000 upon completion of the agreement.


The deal also provides for aggregate potential milestone payments of up to $3.6 million, as well as royalties on commercial sales.

Related News